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automated testing platform
M. Goldman, I. Resz, J. Cote, G. Ochoa, and N. Angus
Because of the variability of D expression, one method may be 
inadequate to correctly classify donors with variant RHD alleles. 
We evaluated the use of a solid-phase automated platform 
(ImmucorGamma Galileo) to confirm D– test results obtained 
on first-time donors on the Beckman Coulter PK7300 automated 
microplate test system. Samples with discordant results were 
analyzed by serologic tube methods, RHD genotyping using the 
BLOODchip platform (Progenika), and, if necessary, sequencing. 
We estimated the number of cases of alloimmunization in 
women younger than 50 years likely to be prevented by the 
addition of Galileo testing. From May 2011 to May 2012, 910,220 
donor samples were tested; 15,441 were first-time donors with 
concordant D– results. Five donors tested D– on the PK7300 
and weak D+ on the Galileo; one was found to be a false positive 
on further testing. On manual testing, the other four donors 
had positive indirect antiglobulin test results with one to three 
of the antisera used and were C+. On BLOODchip testing, two 
donors were classified as D+, and two were assigned a “no call.” D 
variants included weak D type 67, weak D type 9, and two novel 
variants. Approximately 10 percent of D– units are transfused to 
women younger than 50 years. Assuming an alloimmunization 
rate of 30 percent, use of the Galileo would prevent approximately 
one alloimmunization every 5 to 6 years in this patient group. 
We conclude that the yield of preventing alloimmunization in 
this population by adding a second automated serologic testing 
platform is very low. Immunohematology 2013; 29:97–100.
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D is one of the most immunogenic blood group antigens, 
and may cause both hemolytic transfusion reactions and 
hemolytic disease of the fetus and newborn (HDFN). D typing 
can be problematic because the distinction between D+ and 
D– individuals is not always clear.1 Approximately 1 percent 
of white people carry variant RHD alleles, which may lead to 
reduced antigen expression.2,3 The more than 160 different 
RHD alleles that have been described may result in reduced 
antigen density (so-called weak D phenotypes) or qualitatively 
distinct D antigens missing some D epitopes (so-called partial 
D phenotypes). In addition to genetic variability, variable 
typing results may be caused by use of different typing reagents 
and methods. Monoclonal reagents generally give stronger 
reactivity than polyclonal reagents but are directed against 
a single epitope, and therefore may miss certain variants; 
therefore blends of more than one monoclonal reagent or 
monoclonal/polyclonal blends are currently used. Testing to 
detect D is performed by immediate spin (IS); so-called weak 
D testing to detect reduced D expression is performed by the 
indirect antiglobulin test (IAT).1
The classification of individuals as D+ or D– depends not 
only on laboratory results but also on the underlying reason for 
performing the typing. Standards from both the AABB and the 
Canadian Standards Association (CSA) require blood donors 
who appear to be D– to be tested by a method to detect weak D 
expression.4,5 Only donors with negative results are classified 
as D–. The rationale behind these standards is the concern 
that the red blood cells (RBCs) of some donors with variant 
antigen expression may carry enough D to alloimmunize D– 
recipients.
Canadian Blood Services (CBS) tests approximately 
1,000,000 donor samples a year for ABO and D using an 
automated microplate system, the PK7300 (Beckman Coulter, 
Inc., Brea, CA). Two anti-D reagents were used to perform 
testing. First-time donors who appeared to be D– had manual 
tube testing done by both IS and IAT. More recently, the reagents 
used for automated testing on the PK7300 machine have been 
licensed to detect weak D expression. Because of concerns 
that one method may be inadequate to classify all donors with 
variant D alleles as D+, we performed an evaluation of the yield 
of identifying D+ donors by adding an automated solid-phase 
platform (Galileo, ImmucorGamma, Norcross, GA) to confirm 
typing of D– first-time donors. Samples with discordant results 
by the two automated methods were investigated further 
using manual serologic methods and genotyping. Because the 
ultimate goal of testing is not simply to identify variants but 
to prevent alloimmunization, particularly of girls and women 
of childbearing age, we also estimated the number of cases of 
alloimmunization likely to be prevented a year by testing using 
the solid-phase platform in addition to the PK7300.
Materials and Methods
Automated Testing
Blood samples in EDTA tubes were drawn from the 
diversion pouch of donor collection kits and sent to one of 
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two national donor testing laboratories. Routine ABO and D 
testing was performed on the Olympus PK7300 (Beckman 
Coulter) following manufacturer’s instructions and reagent 
package inserts. Samples were tested by the hemagglutination 
sedimentation method for D typing using the anti-D 
monoclonal blend reagent (IgM and IgG human monoclonal 
blend, composed of clones P3X61, P3X21223B10, P3X290, 
and P3X35) and the anti-D (PK1) monoclonal IgM reagent 
(clone P3X61; DIAGAST, Loos Cedex, France). Samples 
from first-time donors with a valid ABO group and D– result 
with both reagents were tested on the automated solid-phase 
platform (Galileo, ImmucorGamma), following manufacturer’s 
instructions and the reagent package inserts. Weak D 
testing was performed by the IAT using one of the Immucor 
monoclonal D reagents (anti-D Series 4 [IgG, IgM monoclonal 
blend, clones MS201 and MS26], ImmucorGamma).
Manual Testing
Donor samples testing weak D+ on the Galileo were 
investigated further using manual tube testing in our National 
Immunohematology Reference Laboratory (NIRL). Tube 
testing was done by both IS and IAT using three different 
anti-D reagents in accordance with the manufacturers’ package 
inserts: an IgM (D175-2) and IgG (D415 1E4) monoclonal 
blend (Novaclone, Dominion Biologicals Limited, Dartmouth, 
Nova Scotia, Canada); an IgM (GAMA401) and IgG (F8D8) 
monoclonal blend (Gamma-clone, ImmucorGamma); and a 
blend of monoclonal IgM (MAD2) and polyclonal human IgG 
anti-D (Bioclone, Ortho Clinical Diagnostics, Raritan, NJ).
Genotyping and DNA Sequencing
Samples with discordant D results were also sent for 
RHD genotyping to the Novartis/Progenika, Inc., reference 
laboratory (Medford, MA). Samples were analyzed by 
the Progenika BLOODchip Reference assay. BLOODchip 
Reference is a polymerase chain reaction– and hybridization-
based genotyping test in oligonucleotide microarray format 
that interrogates 116 polymorphisms in genes encoding RBC 
antigens. For the RHD gene, it interrogates 72 polymorphisms 
that encode 23 D–, 20 weak D, 34 partial D, and 8 Del variants. 
DNA sequencing was performed by the standard Sanger 
dideoxy method with specific primers that bind to intron 
regions flanking RHD exons 5, 6, and 7.
Estimation of Alloimmunization
The retention rate for first-time donors, mean frequency 
of whole blood donations per year per donor, and total number 
of RBCs issued per year were extracted from the CBS Progesa 
database, using our data warehouse. The percentage of RBC 
units transfused per year to women younger than 50 years 
was estimated using data from two sources: from the British 
Columbia (BC) Provincial Blood Coordinating Office (PBCO), 
which stores data on all transfusions in the province of BC, 
the data for a 2-year period (April 2010 to March 2012: 
50,978 distinct recipients and 269,330 RBC units transfused); 
and from the McMaster University Hospital database of 
all transfusions in three large hospitals in the McMaster 
University Hospital system, data from a 3-year period in the 
city of Hamilton, Ontario (January 2009 to January 2012: 
15,058 recipients and 76,702 RBC units transfused).
Results
During a 1-year period starting in May 2011, approximately 
910,220 samples from whole blood donations were tested 
on the PK7300. Of these, 15,441 were first-time donors who 
tested D– on both the PK7300 and Galileo. Five donors tested 
D– on the PK7300 and weak D+ on the Galileo. One of these 
donors was found to be D– on manual testing and genotyping, 
and therefore is considered to be D–, with a falsely positive 
test result on the Galileo. Testing results on the Galileo for 
the other four donors, shown in Table 1, gave 2+ to 4+ results 
by the IAT. On manual tube testing, donor 1 reacted by IAT 
with all three antisera, whereas donors 2, 3, and 4 reacted by 
IAT with only one or two of the three antisera. Interestingly, 
all four donors were found to be C+ on extended Rh typing. 
On genotyping using the BLOODchip, donors 1 and 3 were 
classified as D+, whereas donors 2 and 4 were assigned a “no 
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reference DNA sequencingIS IAT IS IAT IS IAT
1 3+ 0 1+ 0 1+ 0 1+ Ccee D+ Variant of exon 7, RHD*1018A
2 4+ 0 1+ 0 0 0 1+ Ccee No call Variant of exons 5,6, RHD*712A,809G
3 3+ 0 0 0 1+ 0 0 Ccee D+ Weak D, type 67
4 2+ 0 0 0 1+ 0 1+ Ccee No call Weak D, type 9
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call.” On DNA sequencing, donor 1 was found to have a novel 
variant of exon 7 RHD*1018A, similar to RHD*1018A, 1019T 
(weak D type 30). Donor 2 was found to have a novel variant 
of exons 5 and 6, RHD*712A, 809G. A similar listed variant, 
RHD*712C, 809G, was reported in a large French study in 
which direct sequencing was performed on 806 samples with 
ambiguous D phenotypes.6 Finally, donors 3 and 4 exhibited 
known weak D genotypes type 67 and type 9, respectively.
Estimation of Alloimmunization of Female Recipients 
Younger Than 50 Years
Table 2 summarizes the number of female recipients 
younger than 50 years that may have been alloimmunized, if 
the four donors with D-expressing variants had been classified 
as D– based on PK7300 testing. The return rate for new donors 
at CBS is approximately 50 percent, whereas the average 
donor donates two whole blood units annually (Tony Steed, 
CBS, Marketing and Recruitment, personal communication). 
Therefore, we would expect these four donors to contribute 
the initial four units plus two additional units during the 
year. In the province of BC, female recipients younger than 50 
years represent 10.1 percent of patients being transfused and 
receive 9.3 percent of transfused RBC units (Tanya Petraszko, 
BCBlood Coordinating Office, personal communication). In 
Hamilton area hospitals, female recipients younger than 50 
represent 10.6 percent of patients being transfused and receive 
10.6 percent of units transfused (Nancy Heddle, McMaster 
University Transfusion Research Program, personal 
communication). Extrapolating these numbers nationally, 
women younger than 50 would receive approximately 10 
percent of distributed D– units, or 10,306 D– units per year, of 
which 0.60 would be discordant. The exact alloimmunization 
potential of each of these D variants is unknown. A D+ unit, 
with the normal number of D sites, would be expected to cause 
alloimmunization of approximately 30 percent of recipients.7 
The alloimmunization rate for these variant D units is likely to 
be less. However, using an alloimmunization rate of 30 percent, 
0.18 female recipients younger than 50 could be alloimmunized 
annually. This rather simplistic analysis assumes that the 
percentage of D– units transfused to women younger than 50 
is similar to the percentage of all units transfused to this group. 
Additionally, because a large percentage of D– units have had 
extended Rh typing and have the results printed on the unit 
label, these C+ units may not be selected for transfusion of this 
group.
Discussion
In this study, 4 of 15,441 (0.026%) samples with D– results 
on the PK7300 typed as weak D+ on the solid-phase Galileo 
platform. These donors also had positive results by the IAT 
in tube testing using one or more available reagents, although 
no reagent would have detected all four donors. Additionally, 
two of these donors have unreported D variants. These data 
illustrate that no one method will detect all the variants of the 
extremely polymorphic Rh system.
Our donor population is primarily white and of European 
origin. Therefore, we would expect approximately 0.4 to 0.8 
percent of the donors to be weak D variants, predominantly 
type 1, 2, or 3, as described in the European literature. However, 
none of these variants was found in the four discordant donors. 
This suggests that the common D variants are being detected 
and classified as D+ by PK7300 testing, as has been shown to 
occur when using the PK7200 machine.8
Determination of the number of female recipients younger 
than 50 years who might be alloimmunized if Galileo weak D 
testing was stopped is difficult because the exact immunization 
rate associated with the four D variants detected is unknown. 
However, even assuming very conservatively that 30 percent 
of recipients of these units would be alloimmunized, this 
would result in one female recipient younger than 50 being 
alloimmunized every 5 to 6 years.
Interestingly, all four donors were C+. The presence of C is 
a well-known cause of reduced D expression for already weak 
D variants.1,9,10 Indeed, it has been proposed that individuals 
who are D– but C+ or E+ should undergo genotyping to detect 
D variants.9,10 Extensive phenotyping of D– units for C, c, E, 
e, and K is performed at CBS; the results are printed on the 
unit label once testing has been performed on two donations. 
Therefore, it would be possible to simply select rr (ccee) units 
for transfusion to women younger than 50 years because the 
majority of these would be true D– units. An advantage to 
Table 2. Estimation of the number of female recipients <50 years 
old alloimmunized annually
Donors with false D– variants 4
Donations per year (new donors) 1.5
Number of false D– units 4 × 1.5 = 6
Total D– units distributed 103,060
Approx. number of units transfused to 
women <50 years
103,060 × 0.1 = 10,306
False D– units transfused to women  
<50 years
6 × 10,306/103,060 = 0.60
Alloimmunization
If 30% of recipients alloimmunized 0.60 × 0.3 = 0.18
Time between alloimmunizations 1/0.18 = 5–6 years
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selecting rr units would be the avoidance of other very weak 
D variants that may be found by genotyping but are missed 
by the PK7300, the Galileo, or other serologic methods used 
for testing.11–13 Additionally, use of rr units would avoid C and 
G alloimmunization caused by transfusion in C– recipients. In 
some European countries, routine matching for C, c, and K is 
done for transfusion of women younger than 50. This approach 
would have the added advantage of avoiding alloimmunization 
to c in CC patients.11
We conclude that the yield of identifying D+ donors by 
adding an automated solid-phase platform to confirm typing 
of D– first-time donors is extremely low. Matching for C 
and K would likely have a larger impact on reducing HDFN. 
Strategies for prevention of alloimmunization may change in 
the future, with the ongoing development of high throughput, 
inexpensive genotyping methods that could be used to 
routinely screen blood donors.
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